Image source: © Subbotina | Megapixl.com
Highlights
- MVF intends to expand its presence in South-East Asian market
- In FY24, the company recorded net loss after tax of AUD 5.9 million
- MVF’s share price increased by nearly 2.11% to AUD 1.21 apiece on 23 October 2024
Monash IVF Group Limited (ASX:MVF) provides fertility and reproductive services in Australia. The company provides multiple specialised services including gynaecological ultrasound, diagnostic obstetric and fertility treatments. The company focuses on expanding its presence in South-East Asian market.
Today, MVF’s share price has increased by nearly 2.11% to AUD 1.21 apiece. Over the past one year, its share price has dropped by 5.47% and in the past six months, shares have declined by around 19.87%.
On 22 August 2024, MVF share price recorded a fall of approximately 10%, following the class action update and financial year 2024 results.
Class action
Monash IVF has reached a settlement of AUD 56 million in response to allegations that it used faulty genetic testing and destroyed potentially viable embryos. The class action involved over 700 patients across Australia, claiming that the company improperly discarded their embryos.
As part of the settlement, Monash IVF has not admitted any liability, and the agreement remains subject to approval by the Supreme Court.
FY24 results
In FY24, the company recorded 19.4% YoY increase in revenue to AUD 255 million, 13.7% YoY rise in underlying EBIT to AUD 43.3 million and 17.4% YoY growth in underlying NPAT to AUD 29.9 million. The revenue growth was driven by industry expansion, higher prices, contribution from the PIVET and Fertility North acquisitions and market share gains.
The period recorded net loss after tax of AUD 5.9 million. Despite net loss, the company announced final dividend of 2.5 cents per share, up 13% from prior final dividend.

Outlook
The group expects growth in revenue and underlying NPAT in FY25, despite flat new patient registrations in the 2HFY24, compared to 2HFY23 (excluding acquisitions). This growth is anticipated due to several factors: a full year contribution from the Fertility North acquisition, which was concluded in March 2024, contributions from fertility specialists, and ongoing efforts to attract new specialists in FY25. Additionally, increased contributions from newly opened day surgeries as theatre utilization improves, alongside investments in genetics and expanded donor activity, are also expected to drive growth.
Share performance of MVF

MVF Daily Technical Chart, Source: EODHD/Others
Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 23 October 2024. The reference data in this report has been partly sourced from EODHD/Others.






Please wait processing your request...